Inhibikase Therapeutics Updates Corporate Presentation (Reg FD)

What Happened
Inhibikase Therapeutics, Inc. (IKT) filed a Current Report on Form 8‑K on September 8, 2026 (Item 7.01) to disclose that it updated its corporate presentation for use in meetings with investors, analysts, and others. The updated presentation is furnished as Exhibit 99.1 to the 8‑K.

Key Details

• Filing date: September 8, 2026 (Form 8‑K, Item 7.01 — Regulation FD Disclosure).
• Exhibit: Updated corporate presentation furnished as Exhibit 99.1 (dated September 2026).
• Administrative exhibit: Inline XBRL cover page interactive data file included (Exhibit 104).

Why It Matters
The Form 8‑K indicates Inhibikase has provided an updated set of materials for investors and analysts; the presentation itself is now publicly available as an exhibit to the filing. Investors who want the company’s latest messaging, strategic highlights, or program updates should review Exhibit 99.1 in the 8‑K to see the current information the company is using in outreach.